{rfName}
Ra

Indexed in

License and use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Tuñon Fernandez, Jose LuisAuthorFuster VAuthor

Share

March 9, 2022
Publications
>
Article

Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

Publicated to:European Heart Journal-Cardiovascular Pharmacotherapy. 8 (3): 291-301 - 2022-01-01 8(3), DOI: 10.1093/ehjcvp/pvab060

Authors: Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, Anguita M, Fernández-Vázquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Pérez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Agüero J, Pocock S, Ottani F, Fuster V, Ibáñez B, REBOOT-CNIC investigators

Affiliations

Cardiology Department, Hospital Marques de Valdecilla, Santander, IDIVAL, Spain. - Author
Cardiology Department, Hospital Ruber Juan Bravo Quironsalud UEM, Madrid, Spain. - Author
Cardiology Department, Hospital Universitari Son Espases - IDISBA, Palma de Mallorca, Spain. - Author
Cardiology Department, Hospital Universitario de León, León, Spain. - Author
Cardiology Department, Hospital Universtitari i Politecnic La Fe, Valencia, Spain. - Author
Cardiology Department, Hospital Virgen de la Arrixaca, IMIB-Arrixaca and University of Murcia, Murcia, Spain. - Author
Cardiology Department, Ospedale Guglielmo da Saliceto, Piacenza, Italy. - Author
Cardiology Department, Ospedale S. Anna e S. Sebastiano, Caserta, Italy. - Author
Cardiology Department, Ospedale Vizzolo Predabissi di Melegnano, Milan, Italy. - Author
Cardiology Department, University Hospital Álvaro Cunqueiro, Vigo, Spain. - Author
Cardiology Department, University Hospital of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain. - Author
Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, NY, USA. - Author
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. - Author
CIBER de Enfermedades CardioVasculares (CIBERCV), Madrid, Spain. - Author
Department of Cardiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma, Barcelona, Spain. - Author
Department of Cardiology, Hospital Universitario A Coruña, A Coruña, Spain. - Author
Department of Cardiology, Hospital Universitario de Burgos, Burgos, Spain. - Author
Department of Cardiology, Hospital Universitario Reina Sofía de Cordoba, Córdoba, Spain. - Author
Department of Cardiovascular Medicine. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. - Author
London School of Hygiene & Tropical Medicine, London, UK. - Author
NULL - Author
Servicio de Cardiología, Hospital Universitario de Canarias, Tenerife, Spain. - Author
See more

Abstract

There is a lack of evidence regarding the benefits of β-blocker treatment after invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF).TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fraction (REBOOT) trial is a pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical trial testing the benefits of β-blocker maintenance therapy in patients discharged after MI with or without ST-segment elevation. Patients eligible for participation are those managed invasively during index hospitalization (coronary angiography), with LVEF >40%, and no history of heart failure (HF). At discharge, patients will be randomized 1:1 to β-blocker therapy (agent and dose according to treating physician) or no β-blocker therapy. The primary endpoint is a composite of all-cause death, nonfatal reinfarction, or HF hospitalization over a median follow-up period of 2.75 years (minimum 2 years, maximum 3 years). Key secondary endpoints include the incidence of the individual components of the primary composite endpoint, the incidence of cardiac death, and incidence of malignant ventricular arrhythmias or resuscitated cardiac arrest. The primary endpoint will be analyzed according to the intention-to-treat principle.The REBOOT trial will provide robust evidence to guide the prescription of β-blockers to patients discharged after MI without reduced LVEF.© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Keywords

?-blockersAcute myocardial infarctionAdrenergic beta-antagonistsHumansLeft ventricular ejection fractionMyocardial infarctionProspective studiesRandomized clinical trialStroke volumeVentricular dysfunction, leftVentricular function, leftΒ-blockers

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal European Heart Journal-Cardiovascular Pharmacotherapy due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 26/278, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 4.52. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 8.6 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 17.73 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-06, the following number of citations:

  • WoS: 17
  • Scopus: 37
  • Europe PMC: 8

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-06:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 39.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 44 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 37.7.
  • The number of mentions on the social network X (formerly Twitter): 23 (Altmetric).
  • The number of mentions in news outlets: 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/716490

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Italy; United Kingdom; United States of America.